PHILADELPHIA, PA — Latus Bio, Inc. has unveiled groundbreaking research on a novel adeno-associated virus (AAV) capsid variant, AAV-Ep+, which shows significant promise for advancing gene therapy ...
Adeno-associated virus (AAV) preparations remain highly heterogeneous through upstream and downstream bioprocessing phases. Characterizing empty, partial, full, overfilled capsids and encapsulated ...
Watch this dynamic webinar for valuable insights into characterizing the stability of an engineered adeno-associated virus (AAV) serotype under moderate thermal stress and physiological solution ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential of genetic medicine, ...
"CMRI has pioneered the work of establishing barcoded AAV capsid kits, which allow for NGS-based parallel evaluation of large numbers of AAVs for their performance at both DNA (proxy for cell entry) ...
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Apertura has licensed its novel TfR1 capsid (TfR1 CapX) to partners targeting CNS disorders TfR1 CapX enables broad brain distribution via intravenous dosing, meeting the urgent need for a ...
The adeno-associated virus (AAV) has evolved overlapping genes to maximize its genome use, as with the recently-discovered ORF in the cap gene which encodes a membrane-associated accessory protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback